Navigation Links
QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy
Date:5/22/2008

surgery and prior to the first 12mg/8mg dose of Q8003IR, the baseline patient pain intensity (PI) scores averaged 6.6 out of 10 units -- with 10 being the most severe on the Numerical Pain Rating Scale. Analgesic effects as reflected in the maximum pain improvement (PI) for the 12mg/8mg dose of Q8003IR yielded a 2 unit reduction of PI (decreasing patient scores to 4.6) versus a 0.14 unit increase of PI for placebo-treated patients. Placebo patients were treated with ibuprofen, a non-opioid analgesic.

The mean time to confirmed perceptible pain relief for Q8003IR was 42 minutes compared to 4.4 hours for placebo. The duration time of analgesic effect was 6.6 hours for Q8003IR versus 2.8 hours for placebo.

The 12mg/8mgdose data demonstrated that Q8003IR was well tolerated, with a low rate of patient withdrawal (8% discontinuing use due to adverse events and 6% discontinuing use due to efficacy failure) compared to placebo (with 2% discontinuing use due to adverse events and 25% discontinuing use for efficacy failure). Only 2% of 12mg/8mg Q8003IR treated patients experienced somnolence, and no incidences of euphoria were reported. The low level of somnolence and absence of euphoria reported were unexpected outcomes compared to what is typically seen with morphine or oxycodone. The significance of these observations will need to be confirmed in future studies that provide a direct data comparison.

All patients exhibited acceptable respiratory rates with reduction in blood oxygen levels occurring in less than 2% of those on the preferred dose of Q8003IR. Typical of opioid drugs, nausea and vomiting were the most common adverse events. Of patients receiving the 12mg/8mg dose, 56% experienced mild to moderate nausea that diminished over the first few hours of treatment; no incidences of severe nausea were reported. 32% of patients reported vomiting with initial dosing (18% mild to moderate and 14% severe). 20% of patients experienced mild to moderate di
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Premune and Innovet ... licensing agreement for Redonyl ® Ultra. The product, ... veterinary dermatology market, is a nutritional supplement based on ... in dogs and cats. Redonyl ® Ultra is ... has been received positively in the country by veterinarians ...
(Date:8/31/2015)... PLEASANTON, Calif. , Aug. 31, 2015  QT Vascular ... "QT Vascular", and together with its subsidiaries, the ... assembly and distribution of advanced therapeutic solutions for ... today the final results of the below-the-knee ("BTK") ... Registry ("BAR") which were presented on August 15, ...
(Date:8/31/2015)... Aug. 31, 2015   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade cell ... cryopreservation freeze media and a related ... for smart shippers ("BioLife" or the ... an advanced biopharmaceutical company focused on developing and ...
Breaking Medicine Technology:Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5
... Va., Feb. 9, 2011 With generous funding ... Palliative Care Association are partnering to improve pain ... hospitals in The Gambia, Kenya, and Malawi. ... they each have well-established national palliative care organizations, ...
... Design Trends: Technological Advances in Implantable Devices, a UBM Canon Medical Device ... Industry ( MD+DI ) , ... , and OrthoTec , is now on-demand ... 1,092, with an attendance of 50% during the live event held on ...
Cached Medicine Technology:FHSSA and the African Palliative Care Association Launch the First-Ever Pain Management Initiative in The Gambia, Kenya, and Malawi 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 2Now Available: Archived Virtual Event Dedicated to Cutting-Edge Trends in Implantable Medical Devices 3
(Date:9/1/2015)... MO (PRWEB) , ... September 01, 2015 , ... ... Wednesday, September 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis ... and groups with career opportunities will be attending from across the country. All ...
(Date:9/1/2015)... ... 01, 2015 , ... Dr. Trace Curry successfully placed one of the first ... last month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed ... first incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, ...
(Date:9/1/2015)... ... ... Elizabeth Callahan, MD, founder and medical director of SkinSmart Dermatology® , is ... treatment for volume loss in the hands. RADIESSE provides an immediate volumizing effect and ... smooth, natural-looking results that can last up to one year in most patients. Treating ...
(Date:9/1/2015)... ... ... September is Baby Safety Month, and Lightning Labels wants to ... ones' safety top of mind at all times. , Sponsored by the Juvenile Products ... JPMA's Baby Safety Zone website, this year's theme is A Room with A Safe ...
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry is an organized system ... therapy patients. The Registry is being developed by the American Physical Therapy Association (APTA). ... to be selected to contribute FOTO Outcomes measures as one of the primary global ...
Breaking Medicine News(10 mins):Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2
... ... available on XM Satellite Radio Channel 160. This program is produced by KarenZupko & ... ReachMD, a new media communications platform for medical professionals. , ... Chicago, IL (PRWEB) July 15, 2009 ...
... ... the third fastest growing private company by the Indianapolis Business Journal. Mainstreet is a ... since 2006, and from 4 to 145 employees. , ... Cicero, IN (PRWEB) July 15, 2009 -- Mainstreet Property Group ...
... ... application backlogs rise, the impact on people with disabilities grows and adds to financial ... Belleville, ... rate in nine months, according to a quarterly study by Allsup , a ...
... , , , ... in "International Immunopharmacology," reveals why Pycnogenol(R) (pic-noj-en-all), an antioxidant plant ... is effective for reducing inflammation and soothing pain associated with ... Research Institute on Food and Nutrition in Rome, Italy, found ...
... , SAN DIEGO, July 14 CareFusion ... Cardinal Health,s clinical and medical products businesses, today announced the pricing ... notes. The notes consist of the following tranches: , ... principal amount of 4.125% senior notes due 2012 , ...
... , , State must comply - NOT ... OAKLAND, Calif., July 14 In a ruling issued late yesterday ... her June 25, 2009, ruling which halts the State,s plans to cut In-Home ... ruling sends a clear message to the Governor that you can,t ignore the ...
Cached Medicine News:Health News:KarenZupko & Associates, Inc. and ReachMD XM 160 Announce New Radio Programming Series, "Practice Success" hosted by Karen Zupko 2Health News:KarenZupko & Associates, Inc. and ReachMD XM 160 Announce New Radio Programming Series, "Practice Success" hosted by Karen Zupko 3Health News:Growth Despite Economy; Mainstreet Property Group Named One of Indiana's Fastest Growing Companies 2Health News:Growth Despite Economy; Mainstreet Property Group Named One of Indiana's Fastest Growing Companies 3Health News:Income at Risk: Unemployment Reaches Nine-Month High for Those with Disabilities, Reports Allsup 2Health News:Income at Risk: Unemployment Reaches Nine-Month High for Those with Disabilities, Reports Allsup 3Health News:Income at Risk: Unemployment Reaches Nine-Month High for Those with Disabilities, Reports Allsup 4Health News:Income at Risk: Unemployment Reaches Nine-Month High for Those with Disabilities, Reports Allsup 5Health News:Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX 2Health News:Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX 3Health News:CareFusion Prices $1.4 Billion of Senior Notes 2Health News:Federal Judge Orders Schwarzenegger Administration to Comply with Order That Blocks State Reduction for IHSS Worker Wages 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: